A Barchart report today shows unusually heavy volume in out-of-the-money (OTM) put options in Novo Nordisk (NVO), which makes Ozempic and Wegovy (for weight loss and Type 2 diabetes). NVO stock has been moving up, so is it overvalued now?
NVO is at $49.23 in midday trading on July 1, up over 2.6%. In the past 4 weeks, NVO has risen 20% from its low point on June 8 ($41.02).